An RNA-seq study further identified a subpopulation of primitive CML cells expressing CD36 that is quiescent and insensitive to imatinib compared to the CD36-negative subpopulation. This evidence concerns the gene CD36 and chronic myelogenous leukemia, BCR-ABL1 positive.